ABSTRACT
Background Circulating markers of immune and endothelial activation risk stratify infection syndromes agnostic to disease aetiology. However, their utility in children presenting from the community remains unclear.
Methods This study recruited children aged 1-59 months presenting with community-acquired acute febrile illnesses to seven hospitals in Bangladesh, Cambodia, Indonesia, Laos, and Viet Nam. Clinical parameters and biomarker concentrations were measured at presentation. The outcome measure was death or receipt of vital organ support within two days of enrolment. Prognostic performance of endothelial (Ang-1, Ang-2, sFlt-1) and immune (CHI3L1, CRP, IP-10, IL-1ra, IL-6, IL-8, IL-10, PCT, sTNFR-1, sTREM-1, suPAR) activation markers, WHO Danger Signs, and two validated severity scores (LqSOFA, SIRS) was compared.
Results 3,423 participants were recruited. 133 met the outcome (weighted prevalence: 0.34%; 95% CI 0.28-0.41). sTREM-1 exhibited highest prognostic accuracy (AUC 0.86; 95% CI 0.82-0.90), outperforming WHO Danger Signs (AUC 0.75; 95% CI 0.70-0.80; p < 0.001), LqSOFA (AUC 0.74; 95% CI 0.70-0.78; p < 0.001), and SIRS (AUC 0.63; 95% CI 0.58-0.68; p < 0.001). Discrimination of immune and endothelial activation markers was particularly strong for children who deteriorated later in the course of their illness. Compared to WHO Danger Signs, an sTREM-1-based triage strategy improved recognition of children at risk of progression to life-threatening infection (sensitivity: 0.80 vs. 0.72), while maintaining comparable specificity (0.81 vs. 0.79).
Conclusions Measuring circulating markers of immune and endothelial activation may help earlier recognition of febrile children at risk of poor outcomes in resource-constrained community settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MSF maintained a sponsor-investigator role for the study. The Wellcome Trust had no role in study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval granted by: Medecins Sans Frontieres Ethical Review Board; Oxford Tropical Medicine Research Committee; International Centre for Diarrhoeal Disease Research, Bangladesh; Angkor Hospital for Children Research Committee; Cambodian National Ethics Committee for Health Research; Indonesian Medical and Health Research Ethics Committee; Lao PDR National Ethics Committee for Health Research; University of Medicine and Pharmacy at Ho Chi Minh City; Viet Nam National Children's Hospital Ethics Committee for Biomedical Research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Members of the Spot Sepsis Investigator Group are listed in the appendix
DATA SHARING
De-identified, individual participant data from this study will be available to researchers whose proposed purpose of use is approved by the data access committees at Médecins Sans Frontières and the Mahidol-Oxford Tropical Medicine Research Unit. Enquiries or requests for the data may be sent to data.sharing{at}london.msf.org and datasharing{at}tropmedres.ac. Researchers interested in accessing biobanked samples should contact the corresponding author who will coordinate with the Spot Sepsis Sample Use Committee.
